Additional file 1: Table S1. of The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer

Combined SW IV-134 and gemcitabine therapy induces a moderate decrease in WBC count and has no effect on the other CBC parameters in tumor-bearing mice. Complete blood count (CBC) of immunocompromised nude mice treated daily with SW IV-134 and weekly gemcitabine for 3 weeks compared to vehicle (control). WBC is reduced in the drug group, with mean = 2.4 compared to 4.7 in the control group (p = 0.02). The differences in the rest of cell counts between the two groups were not statistically significant. (PDF 75 kb)